Permeable membrane phosphate analogues, pharmaceutical ingredients containing permeable membrane phosphate analogues, and methods for treating diseases such as ischemic ischemia and heart failure； Neurodegenerative disorders and genetic disorders affect the pentachloroenzyme system, including the extensive management of calcium phosphate analogues and their pharmaceutical components. Treatment of genetic diseases affecting the quininase system, for example,A disorder of a cretin transmitter or a disorder of cretin synthesis, including the management of phosphine analogues and their pharmaceutical components. 1. Claim 1: a formula compound (1),Formula (1a),Formula (2)Formula (3) or one of its salts； pharmaceutically acceptable solution, ceramic photometer or stereoisomer: wherein, formula (1) compounds are as follows: res-ch8323o-cd8323a；R1 is hydrogen or 2-C (O) OR-C (O) R-C (O) OCH (CH) OC (O) (CH) CH (R) NH-C (O) OCH (CH₃) OC (O) (CH₂) ₘCH (R¹¹) N (H) C (O) (CH₂) ₘCH (R¹¹) NH₂,-CH (CH₃) O-C (O) (CH₂) ₘCH (R¹¹) N (H) C (O) (CH₂) ₘCH (R¹²) N (H) C (O) (CH₂) ₘCH (R¹³) NH₂,-COC (CH) CH R-Coch8322； - ch8322； - r8313 or compounds selected from the formula group (4)；N is an integer from 1 to 2； m is an integer from 0 to 1； each R 1,R¹² and R¹³ is, independently, an amino acid side chain； R¹⁹ is hydrogen, -C₁₋₈-alkyl or -C₁₋₆-alkyl,a. Replaced by a major hydroxyl, anthrax, or ammonia group； each R2 is an independent hydrogen, hydrocarbon c833318321； andC₁₋₁₂-substituted alkyl, C₁₋₁₂-heteroalkyl,C₁₋₁₂-substituted heteroalkyl, C₃₋₁₂-cycloalkyl,C₃₋₁₂-substituted cycloalkyl, C₄₋₂₀-cycloalkylalkyl C₄₋₂₀-substituted cycloalkylalkyl, C₄₋₂₀-heterocycloalkylalkyl,e. Straight ring tequila；C₅₋₁₂ substituted aryl, C₅₋₁₂ heteroaryl,C₅₋₁₂ substituted heteroaryl, C₆₋₂₀ arylalkyl,C₆₋₂₀-substituted arylalkyl, C₆₋₂₀-heteroarylalkyl or C₆₋₂₀-substituted heteroarylalkyl； each R³ and R⁴ is independently hydrogen, C₁₋₁₂-alkyl or C₁₋₁₂-substituted alkyl； R²³ is hydrogen, C₁₋₁₂ alkyl,C₁₋₁₂-subst
